References
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
- Di Sabatino A, Biagi F, Gobbi PG, et al. How I treat enteropathy-associated T-cell lymphoma. Blood. 2012;119:2458–2468.
- Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148–155.
- Moffitt AB, Ondrejka SL, McKinney M, et al. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med. 2017;214:1371–1386.
- Malamut G, Verkarre V, Callens C, et al. Enteropathy-associated T-cell lymphoma complicating an autoimmune enteropathy. Gastroenterology. 2012;142:726–729.
- Ciccocioppo R, Croci GA, Biagi F, et al. Intestinal T-cell lymphoma with enteropathy-associated T-cell lymphoma-like features arising in the setting of adult autoimmune enteropathy. Hematol Oncol. 2018;36:481–488.
- Komeda Y, Kashida H, Sakurai T, et al. A case of type II enteropathy-associated T-cell lymphoma in a patient with ulcerative colitis. Am J Gastroenterol. 2017;112:833.
- Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136:81–90.
- Karell K, Louka AS, Moodie SJ, et al. European Genetics Cluster on Celiac Disease. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol. 2003;64:469–477.
- Ko YH, Karnan S, Kim KM, et al. Enteropathy-associated T-cell lymphoma–a clinicopathologic and array comparative genomic hybridization study. Hum Pathol. 2010;41:1231–1237.
- Takeshita M, Nakamura S, Kikuma K, et al. Pathological and immunohistological findings and genetic aberrations of intestinal enteropathy-associated T cell lymphoma in Japan. Histopathology. 2011;58:395–407.
- Roberti A, Dobay MP, Bisig B, et al. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun. 2016;7:12602.
- Swerdlow SH, Jaffe ES, Brousset P, International Lymphoma Study Group. et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol. 2014;38:e60–e71.
- Cheminant M, Bruneau J, Malamut G, et al. NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. Gut. 2018;68:1396–1405.